IRIS
TINARI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.027
EU - Europa 5.908
AS - Asia 5.404
SA - Sud America 847
Continente sconosciuto - Info sul continente non disponibili 719
AF - Africa 97
OC - Oceania 9
AN - Antartide 1
Totale 23.012
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.763
SG - Singapore 2.362
CN - Cina 1.390
IT - Italia 1.224
IE - Irlanda 802
BR - Brasile 665
UA - Ucraina 629
RU - Federazione Russa 607
SE - Svezia 564
VN - Vietnam 563
GB - Regno Unito 526
DE - Germania 469
FR - Francia 464
TR - Turchia 391
IN - India 223
FI - Finlandia 206
CA - Canada 127
HK - Hong Kong 104
BD - Bangladesh 92
NL - Olanda 69
BE - Belgio 63
PL - Polonia 62
MX - Messico 60
AR - Argentina 56
AT - Austria 54
JP - Giappone 53
IQ - Iraq 44
CZ - Repubblica Ceca 41
ES - Italia 36
ZA - Sudafrica 35
CO - Colombia 31
EC - Ecuador 23
LT - Lituania 23
JM - Giamaica 19
PK - Pakistan 19
ID - Indonesia 18
EG - Egitto 17
UZ - Uzbekistan 17
VE - Venezuela 16
CL - Cile 15
KR - Corea 14
SA - Arabia Saudita 13
PE - Perù 12
UY - Uruguay 12
AE - Emirati Arabi Uniti 11
GT - Guatemala 11
PY - Paraguay 11
MA - Marocco 10
MY - Malesia 10
AU - Australia 9
CR - Costa Rica 9
EU - Europa 9
GR - Grecia 9
KE - Kenya 9
PT - Portogallo 9
IL - Israele 8
IR - Iran 8
PH - Filippine 8
RO - Romania 8
TN - Tunisia 8
CH - Svizzera 7
EE - Estonia 7
JO - Giordania 7
NP - Nepal 7
TT - Trinidad e Tobago 7
AL - Albania 6
HN - Honduras 6
SV - El Salvador 6
BG - Bulgaria 5
BO - Bolivia 5
DZ - Algeria 5
KZ - Kazakistan 5
LB - Libano 5
NI - Nicaragua 5
TH - Thailandia 5
TW - Taiwan 5
AZ - Azerbaigian 4
OM - Oman 4
BY - Bielorussia 3
ET - Etiopia 3
GE - Georgia 3
MT - Malta 3
SN - Senegal 3
BA - Bosnia-Erzegovina 2
DO - Repubblica Dominicana 2
GD - Grenada 2
HU - Ungheria 2
KW - Kuwait 2
LU - Lussemburgo 2
MD - Moldavia 2
PS - Palestinian Territory 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AQ - Antartide 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
BZ - Belize 1
CI - Costa d'Avorio 1
CM - Camerun 1
Totale 22.281
Salva come PNG Salva come JPEG
Città #
Singapore 1.793
San Jose 1.197
Chandler 959
Dublin 785
Jacksonville 741
Ashburn 617
Dallas 433
Beijing 372
Council Bluffs 343
Princeton 319
Southend 294
Los Angeles 257
Santa Clara 221
Nanjing 220
Izmir 212
The Dalles 194
Munich 188
Pescara 188
Ann Arbor 178
New York 170
Ho Chi Minh City 162
Chieti 159
Wilmington 147
Buffalo 140
Dearborn 134
Hanoi 126
Altamura 121
Boardman 119
Cambridge 111
Tongling 91
Hong Kong 89
Moscow 74
São Paulo 72
Nanchang 71
Phoenix 70
Helsinki 67
Brussels 59
Woodbridge 58
Orem 54
Redondo Beach 54
Rome 51
Dong Ket 50
Chicago 49
Atlanta 47
Tokyo 46
Montreal 45
Vienna 44
Houston 43
Denver 42
Brooklyn 39
Warsaw 39
Milan 38
Amsterdam 37
Columbus 37
Nuremberg 37
Kimball 34
Shenyang 34
Hebei 33
Brno 32
London 32
Norwalk 32
Ancona 31
San Francisco 31
Boston 30
Da Nang 30
Frankfurt am Main 30
Kunming 29
St Louis 28
Tianjin 28
Washington 28
Chennai 27
Jiaxing 26
Seattle 26
Turku 26
Hefei 25
Johannesburg 25
Falls Church 24
Stockholm 23
Changsha 21
Haiphong 21
Toronto 20
Ascoli Piceno 19
Mexico City 19
Rio de Janeiro 19
Baghdad 18
Hangzhou 18
Manchester 18
Poplar 18
Kingston 17
Montesilvano 17
Hyderabad 15
League City 15
Shanghai 15
Belo Horizonte 14
Brasília 14
Düsseldorf 14
Lappeenranta 14
Mumbai 14
Seoul 14
Tashkent 14
Totale 13.335
Salva come PNG Salva come JPEG
Nome #
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 452
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer 286
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 216
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 210
CD19.CAR-T cell-derived extracellular vesicles express CAR and kill leukemic cells, contributing to antineoplastic therapy 208
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 205
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 196
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 194
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 191
Allergooncology: an expanding research area 186
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 185
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy 182
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 180
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 178
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 176
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 169
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 168
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 168
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10^6 cells/L 167
ERBB3 BINDING ANTIBODY 167
Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells 166
Prognostic relevance of LGALS3BP in human colorectal carcinoma 166
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 165
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 164
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 164
Exosomes as pleiotropic players in pancreatic cancer 164
Occupational allergy: is there a role for nanoparticles? 162
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 159
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 158
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 158
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 156
Multi-omics staging of locally advanced rectal cancer predicts treatment response: a pilot study 155
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 155
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 153
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 152
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 152
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 151
New Targets for Therapy in Pancreatic Cancer 150
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 149
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 148
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 147
A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells 147
Flow Cytometry Detection of Anthracycline-Treated Breast Cancer Cells: An Optimized Protocol 146
Novel inhibitors of pvhl-elongin c binding 146
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 145
An FPSE-HPLC-PDA method for the determination of anticancer drugs in human whole blood, plasma, and urine 143
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 143
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 141
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 141
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 141
Trop-2, Na+/K+ ATPase, CD9, PKCα, cofilin assemble a membrane signaling super-complex that drives colorectal cancer growth and invasion 141
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 140
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 140
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 139
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 139
A Stochastic Model for the HIV/AIDS Dynamic Evolution 138
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 138
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 137
The 2EF Antibody Targets a Unique N-Terminal Epitope of Trop-2 and Enhances the In Vivo Activity of the Cancer-Selective 2G10 Antibody 136
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 136
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 134
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 134
3D-informed targeting of the Trop-2 signal-activation site drives selective cancer vulnerability 133
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 133
Elevated serum levels of a 90,000 daltons tumor-associated antigen in cancer and in infection by human immunodeficiency virus (HIV). 133
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 132
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study 132
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 131
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 131
A Flow cytometric study of early gastric cancer 130
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 129
Principali effetti collaterali delle terapie mediche 129
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 129
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 129
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 129
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 128
Unknown primary tumors 128
Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A “hypothesis-generator” preliminary report 128
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 128
Prognostic value of 90K protein in HIV infection 126
Tumor-derived microvesicles: The metastasomes. 126
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 126
DNA ploidy and S-phase fraction in pulmonary carcinoids. 125
Drug repurposing, an attractive strategy in pancreatic cancer treatment: Preclinical and clinical updates 124
Prognostic value of gender and primary tumor location in metastatic colon cancer 124
Prognostic value of a novel circulating serum 90K antigen in breast cancer 123
Role of 90K protein in asthma and TH2-type cytokine expression. 123
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 123
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 122
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 121
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 120
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 120
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 119
Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study. 118
Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study 118
The Crucial Role of Hereditary Cancer Panel Testing in Unaffected Individuals with a Strong Family History of Cancer: A Retrospective Study of a Cohort of 103 Healthy Subjects 117
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 117
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 117
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 117
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 117
Totale 15.078
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.328
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.328
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022819 0 0 0 174 78 37 35 69 59 22 94 251
2022/20232.683 216 341 202 307 267 483 147 236 300 22 103 59
2023/20241.415 121 46 79 63 85 457 236 54 41 40 15 178
2024/20253.722 178 606 501 105 87 184 344 237 357 216 392 515
2025/20267.366 599 320 802 846 702 464 1.202 420 747 667 404 193
2026/20271.915 196 519 647 553 0 0 0 0 0 0 0 0
Totale 23.012